18 December 2025 : Clinical Research
Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer
Mustafa Ersoy
ABEF 1*
DOI: 10.12659/MSM.950963
Med Sci Monit 2025; 31:e950963
Table 3 Comparison of progression-free survival based on time of nivolumab administration.
| Time of administration | Median progression-free survival (months) | P value |
|---|---|---|
| Before 1 PM | 3.5 | .098 |
| After 1 PM | 3.2 | |
| Progression-free survival was estimated using Kaplan-Meier analysis. The value was calculated using the chi-square (log-rank) test. Statistical significance was set at | ||